WO2003068263A1 - Remedy for hypertension - Google Patents
Remedy for hypertension Download PDFInfo
- Publication number
- WO2003068263A1 WO2003068263A1 PCT/JP2003/001625 JP0301625W WO03068263A1 WO 2003068263 A1 WO2003068263 A1 WO 2003068263A1 JP 0301625 W JP0301625 W JP 0301625W WO 03068263 A1 WO03068263 A1 WO 03068263A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- hypertension
- ncx1
- sea0400
- hydrogen atom
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 108010067207 sodium-calcium exchanger 1 Proteins 0.000 claims description 16
- 102100035088 Sodium/calcium exchanger 1 Human genes 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 108010078791 Carrier Proteins Proteins 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 239000011575 calcium Substances 0.000 description 27
- 239000000872 buffer Substances 0.000 description 13
- -1 2,5-difluorophenyl Chemical group 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000003185 calcium uptake Effects 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 229950008138 carmellose Drugs 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- GYNAVKULVOETAD-UHFFFAOYSA-N n-phenoxyaniline Chemical class C=1C=CC=CC=1NOC1=CC=CC=C1 GYNAVKULVOETAD-UHFFFAOYSA-N 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- GKWLIQDHWRWNRS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC(N)(CO)CO.OCCN1CCN(CCS(O)(=O)=O)CC1 GKWLIQDHWRWNRS-UHFFFAOYSA-N 0.000 description 2
- MEAAWTRWNWSLPF-UHFFFAOYSA-N 2-phenoxypyridine Chemical class C=1C=CC=NC=1OC1=CC=CC=C1 MEAAWTRWNWSLPF-UHFFFAOYSA-N 0.000 description 2
- 102000003669 Antiporters Human genes 0.000 description 2
- 108090000084 Antiporters Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101001030470 Homo sapiens Sodium/calcium exchanger 2 Proteins 0.000 description 2
- 101000588943 Homo sapiens Sodium/calcium exchanger 3 Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102100038538 Sodium/calcium exchanger 2 Human genes 0.000 description 2
- 102100032576 Sodium/calcium exchanger 3 Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000000231 kidney cortex Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000006828 (C2-C7) alkoxycarbonyl group Chemical group 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- NMFFUUFPJJOWHK-UHFFFAOYSA-N 2-phenoxyaniline Chemical class NC1=CC=CC=C1OC1=CC=CC=C1 NMFFUUFPJJOWHK-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010067973 Valinomycin Proteins 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- FCFNRCROJUBPLU-UHFFFAOYSA-N compound M126 Natural products CC(C)C1NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC(=O)C(C(C)C)NC(=O)C(C)OC(=O)C(C(C)C)NC(=O)C(C(C)C)OC1=O FCFNRCROJUBPLU-UHFFFAOYSA-N 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 150000002541 isothioureas Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000023718 relaxation of cardiac muscle Effects 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000013303 salt-sensitive hypertensive rat model Methods 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005922 tert-pentoxy group Chemical group 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- FCFNRCROJUBPLU-DNDCDFAISA-N valinomycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC(=O)[C@H](C(C)C)NC(=O)[C@H](C)OC(=O)[C@@H](C(C)C)NC(=O)[C@@H](C(C)C)OC1=O FCFNRCROJUBPLU-DNDCDFAISA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a novel drug for treating hypertension.
- Intracellular free Ca 2+ is an important ion that controls the contraction of the heart muscle and various smooth muscles, the release of neurotransmitters, and the expression of genes.
- the regulation of Ca 2+ concentration regulates the cell membrane and sarcoplasmic reticulum membrane. It is regulated by Ca 2 + -pump, Ca 2 + channel and Na + / Ca 2 + exchange transporter (NCX).
- NCX Na + / Ca 2 + exchange transporter
- the Na + / Ca 2 + exchange transporter plays an important role in contraction and relaxation of cardiac muscle and vascular smooth muscle (Ann. Rev. Physiol. 52: 467 (1990)).
- NCX Na + / Ca 2 + exchange transporter
- NCX1 protein is expressed in large amounts in the brain, heart, and kidney
- NCX2 protein is mainly expressed in the brain and small amounts in visceral smooth muscle
- NCX3 protein is mainly expressed in the brain and small amounts in skeletal muscle.
- NCX inhibitors isothiourea derivatives such as (2- [2- [4 [nitrobenzyloxy] phenyl] ethyl) isothio-ureamethanesulfonate) (K-BR7943) and 2- [4-[(2,5-difluorophenyl)
- K-BR7943 isothiourea derivatives such as (2- [2- [4 [nitrobenzyloxy] phenyl] ethyl) isothio-ureamethanesulfonate
- SEA0400 2- [4-[(2,5-difluorophenyl)
- the present inventors measured the NCX inhibitory activity of K-BR7943, SEA0400, and the like using Na + / Ca 2 + exchange transporter (NCX) prepared from brain, heart, and kidney.
- NCX Na + / Ca 2 + exchange transporter
- phenoxyaniline derivatives and phenoxypyridine derivatives such as SEA0400 It was found to selectively inhibit heart and kidney-derived NCX as compared to that derived from NCX.
- the present inventors examined various disease models (diabetic rats, salt-sensitive hypertension model, etc.) using the above NC XI selective inhibitor in order to elucidate the relationship between NCX1 and diseases and treatment.
- the salt-sensitive hypertension model it was found that inhibiting NCX1 was effective for lowering blood pressure, and completed the present invention.
- the present invention is a therapeutic agent for hypertension comprising a compound that inhibits Na + / Ca 2 + exchange transporter 1 as an active ingredient.
- R 1 represents a hydrogen atom or an alkoxy group
- R 2 represents a halogen atom or a nitro group
- R 3 represents a hydrogen atom or a halogen atom.
- a pharmaceutically acceptable salt thereof as an active ingredient for treating hypertension.
- the compound that inhibits NCX1 is not particularly limited as long as it is a compound that inhibits kidney-derived NCX1, but in the test described below (Reference Example 3) at a concentration of 3 M. Those that inhibit 50% or more are preferred. Further, a compound that specifically inhibits NCX1 is preferred for the purpose of preventing side effects.
- the compound that specifically inhibits NCX1 refers to a compound that hardly inhibits other receptors, channels and transporters at a concentration that inhibits NCX1, and specifically, for example, Ca + channeK Na at a concentration of 3 M. + channel, K + channel, Na + / H + transporter norepinephrine transporter, Na + , K ATPase, Ca 2 + -ATPase, phosphol ipase A 2 , phospol ipase 5-lipoxygenase, inducible nitric-oxide synthetase ⁇ constitutive nitric-oxide Adenosine receptor.
- Ad renergic receptor, Glutamate receptor, Bradykinin receptor, LTB4 receptor and PAF receptor are preferably not inhibited by 50% or more.
- the measurement method using each ion channel, enzyme and receptor is described in J. Pharmacol. Exp. Ter. Vol. 298, p. 249 (2001) and references cited therein.
- Examples of compounds that specifically inhibit NCX1 include phenoxyaniline derivatives and phenoxypyridine derivatives.
- R 4 , R 5 and R 6 are the same or different and represent a hydrogen atom or a halogen atom, and X is
- R 7 represents a hydrogen atom, a substituted or unsubstituted ( ⁇ to (; 6 alkyl group or a substituted or unsubstituted ( ⁇ to () 6 alkoxy group
- Z represents a nitro group
- an amino group or an NHC ( O) represents a CH 2 R 8 group
- R 8 is a hydrogen atom, a substituted or unsubstituted ⁇ alkyl group, a substituted or unsubstituted ⁇ ( 6 alkoxy group, a halogen atom, a hydroxy group, a C 2 -C 7 acyloxy group, NR 9 R 1Q or
- R 9 and R 1 Q are the same or different hydrogen atom, a substituted or unsubstituted -C 6 alkyl group, a N- methyl-4 Piperijiniru group, R 11 is a hydrogen atom, human Dorokishi group or C 2 ⁇ A C 7 alkoxycarbonyl group; Y represents a methylene group, an epoxy group, a thio group or an NR 12 group, and n represents an integer of 1 to 4.
- R 12 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted phenyl group. Or a pharmaceutically acceptable salt thereof.
- R 1 represents a hydrogen atom or an alkoxy group
- R 2 represents a halogen atom or a nitro group
- R 3 represents a hydrogen atom or a halogen atom.
- alkoxy group means a linear or branched alkoxy group having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, Butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group, neopentyloxy group, tert-pentyloxy group, 1-methylbutoxy group, 2-methylbutoxy group, 1, 2— Examples include a dimethylpropoxy group, a hexyloxy group, and an isohexyloxy group.
- substitution ( ⁇ to ( 6 As the substituent of the alkoxy group, there are a chloro group, a fluoro group, a nitro group, an amino group, a dimethylamino group, a carbonyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a phenyl group, a hydroxy group, a cyano group) And carbamoyl groups.
- the halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- C, and the -C 6 alkyl group a linear or branched alkyl group of from 1 to 6 carbon atoms and meaning taste, for example a methyl group, Echiru group, a propyl group, an isopropyl group, a butyl group, I Sobuchiru group , Sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, And an isohexyl group.
- Substituents-Substituents of the alkyl group include a chloro group, a fluoro group, a nitro group, an amino group, a dimethylamino group, a carboxyl group, a methoxycarbonyl group, an ethoxycarponyl group, a phenyl group, a methoxy group, an ethoxy group, and a hydroxy group And a cyano group and a carbamoyl group.
- the C 2 -C 7 acyloxy group means a linear or branched acyloxy group having 2 to 7 carbon atoms, and the acyl moiety may be cyclic or may contain an aromatic group.
- an acetoxy group, a propionyloxy group, an isopropionyloxy group, a cyclohexyloxy group, a benzoyloxy group and the like can be mentioned.
- the C 2 -C 7 alkoxycarbonyl Cal Poni group means a straight or branched ⁇ Rukokishikarupo two Le group having a carbon number of 2-7, an alkoxyl moiety may be cyclic, comprise an aromatic group May be.
- Examples of the substituent of the substituted phenyl group include a chloro group, a fluoro group, a nitro group, an amino group, a dimethylamino group, a carbonyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a methyl group, an ethyl group, a methoxy group, an ethoxy group and a hydroxy group.
- Examples of compounds that exhibit excellent hypertensive action include
- the compound is a compound that more strongly inhibits NCX1 than NCX2 and NCX3.
- the compound is a compound that more strongly inhibits NCX1 than NCX2 and NCX3.
- IC 5 (Derived from renal cortex)
- IC 50 (derived from brain)
- IC 50 from renal cortex
- IC 5 from myocardium
- the compounds represented by the formulas (1) and (2) are described in WO 98/43943, WO 99/20598, JP-A-10-265460, JP-A-10-218844, JP-A-11-49752, and JP-A-11-92454. According to the manufacturing method described in Can be synthesized.
- the therapeutic agent for hypertension means a therapeutic agent for salt-sensitive hypertension, renal hypertension, essential hypertension, gestational hypertension, and primary aldosteronism.
- the therapeutic agent of the present invention is orally or parenterally prepared in an appropriate pharmaceutical composition form (tablets, pills, capsules, granules, dry syrups, injections, etc.) using known carriers, diluents and the like as appropriate. Can be used
- Solid additives are manufactured using various additives, for example, excipients, disintegrants, binders, lubricants, and coating bases, and are manufactured by stirring granulation, fluidized bed granulation, and crushing granulation. it can.
- an antioxidant if necessary, an antioxidant, a coating agent, a coloring agent, a flavoring agent, a surfactant, a plasticizer, and the like can be added.
- the dosage of the active ingredient of the medicament of the present invention varies depending on the age, body weight, administration form and the like, but it is usually 0.1 to 1000 mg / day for an adult, which is administered once or several times a day.
- the present invention will be described using formulation examples, test examples, and the like, but the present invention is not limited to these test examples and the like.
- Microsomes (1.5 mg / inl) obtained from the cerebrum of a rat (8 weeks old) were pretreated with a buffer containing 160 mM NaCl, and Na was loaded into the membrane vesicles. This suspension
- Canine myocardial vesicles (0.5 mg / ml) were prepared by centrifugation according to Methods enzymology, vol. 157, p. 85 (1988), and solution A (20 mM M0PS-Tris (pH 7.4), 160 mM NaCl) was prepared. or KCl) and allowed to stand at room temperature for about 1 hour to load Na or K into the vesicles.
- sucrose buffer (0.25 mM sucrose, 0.1 lmM PMSF, 10 mM Tris-HCl (pH 7.6)
- remove the coating and isolate the isolated cortex in sucrose buffer. And cut finely.
- homogenizing was performed with a polytron homogenizer. Thereafter, the mixture was centrifuged at 2500 g for 15 minutes, and the supernatant was recovered. Further, the mixture was centrifuged at 24000 g for 20 minutes to recover a white fluffy portion of the pellet. Further, sucrose buf fer was added, and the mixture was homogenized with a dounce homogenizer.
- Preequilibrat ion buffer the BLMV After equilibration (37 ° C, 10 min) (100 NaCl, 40mM KC1, lmM MgS0 4, lOmM glu cose, 5mM HEPES-Tr is (pH7.4)), centrifuged (20000 g, 5min ) To collect the precipitate, and resuspended in a preequilibration buf fer. After re-centrifugation to collect the precipitate, it was resuspended in a preequilibration buf fer.
- the BLMV suspension e xternal medium ( ⁇ ⁇ choline chloride , 40mM KC1, lmM MgS0 4, lOmM glucose , 5 mM HEPES-Tris (pH 7.4), 25 uM valinomycin, lOuM CaCl 2 , lmCi / 1 45 CaCl 2 ), and the uptake was started.
- stop the reaction by adding 2 ml of stop solution (ice-co Id 150 mM C1), and immediately filter through an ultrafiltration membrane (0.45 ⁇ m nitrocellulose filter) to filter BLMV. Recovered above.
- 45 Ca incorporated into BLMV was quantified by the liquid scintillation overnight method.
- Dahl salt-sensitive hypertensive rats (7 weeks old) were fed a 4% NaCl high-salt prepared diet (0.6% for normal diet), and were allowed to drink water freely. Two weeks after the high salt load, after confirming that hypertension was induced, the animals were divided into the following four groups for the experiment.
- the pre-administration values of systolic blood pressure were 140 ⁇ 3, 148 ⁇ 4, 143 ⁇ 3, and U2 ⁇ 4 mmHg in groups I, II, ⁇ , and IV, respectively.
- the blood pressure change rate 1 hour after administration was as follows: vehicle group: -3.8 ⁇ 1.0%, SEA0400 3 mg / kg group: -9.5 ⁇ 1.8%, SEA0400 10 mg / kg group: -12.0 ⁇ 0.9% and SEA0400 30 mg / kg group: -12.7 ⁇ 3.4%, and a significant decrease in blood pressure was observed in the 10 and 30 mg / kg groups as compared to the vehicle group.
- the present invention it is possible to provide a therapeutic agent for hypertension based on a novel mechanism of action, and it is useful for the treatment and prevention of hypertension with few side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003567443A JPWO2003068263A1 (en) | 2002-02-15 | 2003-02-17 | Antihypertensive drug |
US10/504,585 US7183322B2 (en) | 2002-02-15 | 2003-02-17 | Remedy for hypertension |
AU2003211254A AU2003211254A1 (en) | 2002-02-15 | 2003-02-17 | Remedy for hypertension |
EP03705219A EP1475102A4 (en) | 2002-02-15 | 2003-02-17 | Remedy for hypertension |
HK05107011A HK1074775A1 (en) | 2002-02-15 | 2005-08-15 | Remedy for hypertension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-39008 | 2002-02-15 | ||
JP2002039008 | 2002-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003068263A1 true WO2003068263A1 (en) | 2003-08-21 |
Family
ID=27678214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/001625 WO2003068263A1 (en) | 2002-02-15 | 2003-02-17 | Remedy for hypertension |
Country Status (7)
Country | Link |
---|---|
US (1) | US7183322B2 (en) |
EP (1) | EP1475102A4 (en) |
JP (1) | JPWO2003068263A1 (en) |
CN (1) | CN1290581C (en) |
AU (1) | AU2003211254A1 (en) |
HK (1) | HK1074775A1 (en) |
WO (1) | WO2003068263A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153934A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and magnesium |
CN108939075A (en) * | 2018-07-26 | 2018-12-07 | 陕西师范大学 | Application of the NCX1 gene as the pharmaceutical intervention target spot for the treatment of apnea syndrome |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002233376A (en) * | 2001-02-07 | 2002-08-20 | Takeda Chem Ind Ltd | New protein and its dna |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10218844A (en) * | 1997-02-13 | 1998-08-18 | Taisho Pharmaceut Co Ltd | 2-phenoxyaniline derivative |
KR20010005632A (en) * | 1997-03-27 | 2001-01-15 | 우에하라 아끼라 | 2-Phenoxyaniline Derivatives |
US6162832A (en) * | 1997-10-20 | 2000-12-19 | Taisho Pharmaceutical Co., Inc. | 2-Phenoxyaniline derivatives |
JP2000355537A (en) * | 1999-04-16 | 2000-12-26 | Taisho Pharmaceut Co Ltd | Sodium ion/calcium ion exchange system inhibitor |
WO2002024204A2 (en) * | 2000-09-20 | 2002-03-28 | Mitokor | Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
US6423705B1 (en) * | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
-
2003
- 2003-02-17 WO PCT/JP2003/001625 patent/WO2003068263A1/en active Application Filing
- 2003-02-17 JP JP2003567443A patent/JPWO2003068263A1/en active Pending
- 2003-02-17 EP EP03705219A patent/EP1475102A4/en not_active Withdrawn
- 2003-02-17 AU AU2003211254A patent/AU2003211254A1/en not_active Abandoned
- 2003-02-17 CN CNB038037289A patent/CN1290581C/en not_active Expired - Fee Related
- 2003-02-17 US US10/504,585 patent/US7183322B2/en not_active Expired - Fee Related
-
2005
- 2005-08-15 HK HK05107011A patent/HK1074775A1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002233376A (en) * | 2001-02-07 | 2002-08-20 | Takeda Chem Ind Ltd | New protein and its dna |
Non-Patent Citations (4)
Title |
---|
ACTA NEUROCHIRURGICA SUPPLEMENTUM, vol. 60, 1994, pages 289 - 292 * |
DATABASE MEDLINE [online] KASHIWAGI F. ET AL.: "Effect of a new calcium antagonist (SM-6586) on experimental cerebral ischemia", XP002969905, accession no. STN Database accession no. 95067100 * |
See also references of EP1475102A4 * |
YAMASHITA JUNJI ET AL.: "Pre- or Post-ischemic treatment with a novel Na+/Ca2+ exchange inhibitor, KB-R7943, shows renal protective effects in rats with ischemic acute renal failure", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 296, no. 2, February 2001 (2001-02-01), pages 412 - 419, XP002967651 * |
Also Published As
Publication number | Publication date |
---|---|
EP1475102A1 (en) | 2004-11-10 |
AU2003211254A1 (en) | 2003-09-04 |
US20050222268A1 (en) | 2005-10-06 |
JPWO2003068263A1 (en) | 2005-06-02 |
US7183322B2 (en) | 2007-02-27 |
EP1475102A4 (en) | 2007-01-24 |
CN1630533A (en) | 2005-06-22 |
HK1074775A1 (en) | 2005-11-25 |
CN1290581C (en) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5788527B2 (en) | Side effects reducing agent of kinase inhibitor | |
US20190192525A1 (en) | Apilimod compositions and methods for using same | |
JP2009537565A (en) | R (+) and S (-) pramipexole compositions and methods of using the same | |
WO2008026156A2 (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
CN101878030A (en) | Compositions and methods for treating immunological and inflammatory diseases and disorders | |
CA3096156A1 (en) | Use of inhibitors of bcr-abl mutants for the treatment of cancer | |
EP3484467B1 (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
JP2001302514A (en) | Medicament containing phenylethenesulfonamides | |
EP3458040B1 (en) | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist | |
WO2003068263A1 (en) | Remedy for hypertension | |
JP3598116B2 (en) | Pharmaceutical composition for the treatment of tardive dyskinesia and its use | |
PT1359905E (en) | Use of mglur5 antagonists for the treatment of pruritic conditions | |
JP5198852B2 (en) | Pyrazolone compounds useful for the treatment of cerebrovascular disorders associated with cerebral infarction | |
WO2003061700A1 (en) | Remedies for chronic kidney diseases | |
JP3024789B2 (en) | Antihypertensive | |
MX2012013054A (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof. | |
US20040138207A1 (en) | Antitumor agents | |
US11390581B2 (en) | Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate | |
JP2013014549A (en) | Agent for alleviating side effect of anticancer agent | |
JP2006045142A (en) | THERAPEUTIC OR DIAGNOSTIC AGENT WHICH CONTAINS NCX1 INHIBITOR AND USED FOR CIRCULATORY DISORDER ASSOCIATED WITH ENDOGENEOUS Na+PUMP INHIBITOR | |
AU2006261296B2 (en) | Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder | |
JP2003267871A (en) | Radiation hazard-preventing agent | |
JP2006518722A (en) | 1- (2- for treatment of pancreatic cancer, soft tissue sarcoma, testicular tumor, lymphoma, thymoma, Wilms tumor, kidney cancer, melanoma, lung tumor, intracerebral metastasis, head and neck tumor, and breast cancer Method for using chloroethyl) -1-nitroso-3- (2-hydroxyethyl) urea | |
JP2007056003A (en) | New prophylactic or therapeutic agent of cardiac failure | |
JPH09502188A (en) | Methods of treating liver disease and similar conditions with vasodilators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003567443 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038037289 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003705219 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003705219 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10504585 Country of ref document: US |